Respiratory comorbidities and treatments in Duchenne muscular dystrophy: impact on life expectancy and causes of death

Lisa Wahlgren,Anna-Karin Kroksmark,Anders Lindblad,Mar Tulinius,Kalliopi Sofou,Wahlgren, Lisa
DOI: https://doi.org/10.1007/s00415-024-12372-7
2024-04-17
Journal of Neurology
Abstract:Background Duchenne muscular dystrophy (DMD) is a neuromuscular disorder with progressive decline of pulmonary function increasing the risk of early mortality. The aim of this study was to explore the respiratory-related comorbidities, and the effect of these comorbidities and treatments on life expectancy and causes of death. Methods All male patients living in Sweden with DMD, born and deceased 1970–2019, were included. Data regarding causes of death were collected from the Cause of Death Registry and cross-checked with the medical records along with diagnostics and relevant clinical features. Results Hundred and twenty nine patients were included with a median lifespan of 24.3 years. Acute respiratory failure accounted for 63.3% of respiratory-related causes of death. 70.1% suffered at least one pneumonia, with first episode at a median age of 17.8 years. Hypoventilation was found in 73.0% with onset at 18.1 years. 60.5% had their first pneumonia before established hypoventilation. Age at onset of hypoventilation showed a strong correlation with age at first pneumonia. First pneumonia and scoliosis non-treated with scoliosis surgery increased the risk of dying of respiratory-related causes. In 10% of the patients, first pneumonia resulted in acute tracheostomy or early death. Patients treated with assisted ventilation had higher life expectancy compared to untreated patients. Conclusions Our results highlight the importance of identifying subclinical hypoventilation in a timely manner and the importance of an active treatment regime upon clinical signs of pneumonia.
clinical neurology
What problem does this paper attempt to address?
This paper aims to explore the respiratory comorbidities in patients with Duchenne muscular dystrophy (DMD) and their impact on life expectancy and causes of death. ### Research Background DMD is a progressive neuromuscular disease that leads to a gradual decline in lung function, increasing the risk of early death. The study aims to explore the impact of respiratory-related comorbidities and their treatment on the life expectancy and causes of death in DMD patients. ### Main Findings 1. **Sample Information**: The study included 129 Swedish male DMD patients, with a median age of 24.3 years. 2. **Respiratory Failure**: Acute respiratory failure accounted for 63.3% of respiratory-related causes of death, with the median age of first pneumonia onset being 17.8 years. 3. **Hypoventilation**: 73.0% of patients experienced hypoventilation, with a median onset age of 18.1 years. 4. **Relationship Between Pneumonia and Hypoventilation**: 60.5% of patients experienced their first pneumonia before being diagnosed with hypoventilation, and there was a significant correlation between the age of first pneumonia and the onset age of hypoventilation. 5. **Risk Factors**: The first pneumonia and untreated scoliosis increased the risk of respiratory-related death. 6. **Impact of Assisted Ventilation**: Patients receiving assisted ventilation treatment had a significantly improved life expectancy. ### Conclusion The study emphasizes the importance of timely identification of subclinical hypoventilation and suggests proactive treatment measures when clinical symptoms of pneumonia appear. Additionally, assisted ventilation treatment is crucial for improving the survival rate of DMD patients.